WHAT HAVE WE LEARNED FROM GENETICS?: THE STRONG HEART STUDY 4/11/08 LYLE BEST, MD.

Slides:



Advertisements
Similar presentations
CZ5225 Methods in Computational Biology Lecture 9: Pharmacogenetics and individual variation of drug response CZ5225 Methods in Computational Biology.
Advertisements

Genetic research designs in the real world Vishwajit L Nimgaonkar MD, PhD University of Pittsburgh
Genetic Analysis in Human Disease
SUPERSIZED NATION By Jennifer Ericksen August 24, 2007.
The Inheritance of Complex Traits
Chapter 3: Genetic Bases of Child Development
Obesity. What is Obesity Obesity is an excess proportion of total body fat. A person is considered obese when his or her weight is 20% or more above normal.
Office hours Wednesday 3-4pm 304A Stanley Hall. Fig Association mapping (qualitative)
CS177 Lecture 9 SNPs and Human Genetic Variation Tom Madej
Dr. Almut Nebel Dept. of Human Genetics University of the Witwatersrand Johannesburg South Africa Significance of SNPs for human disease.
Aspects of Genetics and Genomics in Cancer Research Li Hsu Biostatistics and Biomathematics Program Fred Hutchinson Cancer Research Center.
Computational Tools for Finding and Interpreting Genetic Variations Gabor T. Marth Department of Biology, Boston College
Positional Cloning LOD Sib pairs Chromosome Region Association Study Genetics Genomics Physical Mapping/ Sequencing Candidate Gene Selection/ Polymorphism.
Human Genetics Overview.
Something related to genetics? Dr. Lars Eijssen. Bioinformatics to understand studies in genomics – São Paulo – June Image:
Human Genomic Variation The Story of SNPs. Single Nucleotide Polymorphisms (SNPs)  In addition to variation in microsatellites (VNTRs), genetic variation.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
University of Utah Department of Human Genetics Pharmacogenomics Louisa A. Stark, Ph.D. Director.
Haplotype Discovery and Modeling. Identification of genes Identify the Phenotype MapClone.
Cholesterol. CHOLESTEROL What is it? How does it cause heart disease? A fat like substance in your blood When there is too much cholesterol in your blood,
Chapter 7 Multifactorial Traits
Genetic Analysis in Human Disease. Learning Objectives Describe the differences between a linkage analysis and an association analysis Identify potentially.
Genes, Environment- Lifestyle, and Common Diseases Chapter 5.
MI: Risk Factors and Primary Prevention. Risk Factors Factors that appear to increase the general population’s chances of experiencing a health problem.
Global impact of ischemic heart disease World Heart Federation, 2011.
Unit 5 – Public Health Chronic Diseases
Bernard Keavney Institute of Human Genetics University of Newcastle, UK. Recent developments in genetic epidemiology relevant to PURE.
Introduction to BST775: Statistical Methods for Genetic Analysis I Course master: Degui Zhi, Ph.D. Assistant professor Section on Statistical Genetics.
Kotseva K, et al. Eur J Cardiovasc Prev Rehabil 2009 Mar 12 [Epub]
Pharmacogenomics Eric Jorgenson.
Computational research for medical discovery at Boston College Biology Gabor T. Marth Boston College Department of Biology
Pharmacogenetics and Pharmacogenomics Eric Jorgenson 2/24/9.
SNPs Daniel Fernandez Alejandro Quiroz Zárate. A SNP is defined as a single base change in a DNA sequence that occurs in a significant proportion (more.
©Edited by Mingrui Zhang, CS Department, Winona State University, 2008 Identifying Lung Cancer Risks.
CS177 Lecture 10 SNPs and Human Genetic Variation
A Genome-wide association study of Copy number variation in schizophrenia Andrés Ingason CNS Division, deCODE Genetics. Research Institute of Biological.
Gene Hunting: Linkage and Association
1 Genes, Environment- Lifestyle, and Common Diseases Chapter 5.
Interactions Eric Jorgenson EPI 217 2/22/11. Outline Gene-Environment Interaction Gene-Gene Interaction Pharmacogenetics Pharmacogenomics.
Genes, Environment, and Common Diseases Chapter 5 Mosby items and derived items © 2010, 2006 by Mosby, Inc., an affiliate of Elsevier Inc.
Personalized Medicine Dr. M. Jawad Hassan. Personalized Medicine Human Genome and SNPs What is personalized medicine? Pharmacogenetics Case study – warfarin.
Finnish Genome Center Monday, 16 November Genotyping & Haplotyping.
Fibrinogen in South Asians Dr Kirti Kain MD MRCP Academic Unit of Molecular Vascular Medicine Leeds University Leeds United Kingdom.
Prof. Dr. H. Schunkert Medizinische Klinik II UK S-H Campus Lübeck Genome-wide association for myocardial infarction.
What’s the Difference? Genetic and Common Diseases.
EGEE-III INFSO-RI Enabling Grids for E-sciencE EGEE and gLite are registered trademarks Genome Wide Haplotype analyses of human.
2005 Utah State Office of Education The Shape Of Things To Come? The Economist – December 13, 2003.
The International Consortium. The International HapMap Project.
Obesity, Nutrition and Nutri-genonmics
Cancer 101: A Cancer Education and Training Program for [Target Population] Date Location Presented by: Presenter 1 Presenter 2.
Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.
Familial coronary artery disease Paul Brennan Clinical Director Northern Genetics Service Newcastle Hospitals NHS Foundation Trust North East and North.
Admixture Mapping Controlled Crosses Are Often Used to Determine the Genetic Basis of Differences Between Populations. When controlled crosses are not.
Circulatory System. Major Parts Heart: muscular organ that pumps blood throughout the body Veins: Carries oxygen-poor blood TO heart O 2 poor blood.
GENETIC MARKERS OF CORONARY ARTERY DISEASE RISK GALYA ATANASOVA MD, PhD DOMINIC JAMES.
Unit 1 – Living Cells.  The study of the human genome  - involves sequencing DNA nucleotides  - and relating this to gene functions  In 2003, the.
Notes: Human Genome (Right side page)
Different microarray applications Rita Holdhus Introduction to microarrays September 2010 microarray.no Aim of lecture: To get some basic knowledge about.
Body-Fat Loss and Weight Control chapter 8. Societal Change During the late 19th century in the United States, human muscle power provided 33% of the.
Drug efficacy is questioned.. Variation in drug responses.
Genome-Wides Association Studies (GWAS) Veryan Codd.
Pharmacogenetics/Pharmacogenomics. Outline Introduction  Differential drug efficacy  People react differently to drugs Why does drug response vary?
Brendan Burke and Kyle Steffen. Important New Tool in Genomic Medicine GWAS is used to estimate disease risk and test SNPs( the most common type of genetic.
All-cause mortality by treatment group
Genetic Testing for the Clinician
Recombination (Crossing Over)
Genome-wide Associations
Exercise: Effect of the IL6R gene on IL-6R concentration
Baseline Characteristics of the Subjects*
A – Demographic, Anthropometric and Clinical correlates of plasma NT-proBNP levels stratified by race: Multivariable Regression Results (Multivariable.
Presentation transcript:

WHAT HAVE WE LEARNED FROM GENETICS?: THE STRONG HEART STUDY 4/11/08 LYLE BEST, MD

THE PROBLEM At least 30,000 genes Among 3 BILLION base-pairs of the human genome. Genes interact with the environment Genes interact with each other Environmental influences alone can cause disease Chance plays a role

GENETIC APPROACHES Heritability –“Does genetics play a role in this situation? If so, how big a role?” Linkage –“Can we find small pieces of chromosomes that are strongly influencing an effect?” Candidate gene –“We think it is a good bet that this particular gene is a factor in X condition. Are these variations in this particular gene associated with X ?”

GENE HUNTERS AT WORK

Karyotype copyright©1999 Children’s Health Care System

SINGLE NUCLEOTIDE POLYMORPHISM...”SNP”

THERE ARE “AT LEAST” 15,000,000 DIFFERENT “SNPs” THAT CAN VARY BETWEEN INDIVIDUALS PROBABLY MOST HAVE NO EFFECT ON OUR BIOLOGY

RECOMBINATION 2 SNPs CAN BE SEPARATED DURING THE PRODUCTION OF SEX CELLS (eg SPERM AND EGGS) THIS IS A NORMAL PROCESS HAPPENS 2 OR 3 TIMES FOR EACH CHROMOSOME

RECOMBINATION “ABCDEFGH” IS CALLED THE “HAPLOTYPE” OR A “BLOCK” OF SNPs “A” AND “H” ARE MORE LIKELY TO BE SEPARATED THAN “A” AND “B” OVER GENERATIONS THE “BLOCKS” GET SMALLER

RECOMBINATION IF “E” IS A DISEASE CAUSING SNP OVER MANY GENERATIONS, IT IS MORE LIKELY TO TRAVEL WITH “D” OR “F” THAN WITH “A OR “H”

THE STRONG HEART STUDY APPROACH: GENOME-WIDE LINKAGE STUDY FAMILY BASED 400+ “MARKER” SNPs ON ALL 23 PAIRS OF CHROMOSOMES DOESN’T REQUIRE “GUESSING” WHICH GENE TO TEST FOR EFFECTS

WHERE IT ALL STARTS

LINKAGE STUDIES EACH OF THESE PUZZLE PIECES REPRESENTS AN INHERITED “BLOCK” OF SNPs A DISEASE-CAUSING GENE MAY TRAVEL WITH ONE OF OUR “MARKER” SNPs

LINKAGE ANALYSIS

GWAS!!....GEEwhat?? GENOME-WIDE ASSOCIATION STUDY THE LATEST “REVOLUTION” TO HIT GENETIC EPIDEMIOLOGY WHY IS IT IMPORTANT?

“GWAS” per family 100,000 or more

“GWAS” 400+ SNPs Up to 2,000,000 SNPs

GWAS THINK OF THE WHOLE HUMAN RACE AS A BIG FAMILY INSTEAD OF HAPLOTYPE “BLOCKS” THAT ARE MILLION BASE-PAIRS LONG THINK OF “BLOCKS” THAT ARE THOUSAND BASE-PAIRS LONG STATISTICAL STANDARDS (p-values) much higher MAY MISS RARE SNPs WITH BIG EFFECTS GENETIC BACKGROUND MORE VARIABLE

GWAS NIH FUNDS MOST BIOMEDICAL RESEARCH IN THE US INCLUDING SHS INSIST ON WORLD- WIDE SHARING OF DATA IF THEY FUND GWAS STUDY MANY TRIBES CLAIM OWNERSHIP OF DATA

GWAS DR. ERIC TOPOL REPORTED PLANS FOR GWAS STUDY OF TRIBES IN SAN DIEGO AREA TARGET: GENETICS OF ADDICTIVE BEHAVIOR TRIBAL GOVERNMENTS SAID TO BE SUPPORTIVE

GWAS PUBLIC CORPORATION TRADED ON NASDAQ AGREEMENT WITH GOVERNMENT OF ICELAND TO ACCESS MEDICAL RECORDS ICELANDERS MUST “OPT OUT” DEVELOPED DRUGS WILL BE PROVIDED FREE TO ICELAND

TYPE 2 DIABETES NOVEL GENE (TCF7L2) DISCOVERED BY deCODE CONFIRMED IN OTHER STUDIES 2 “T” ALLELES INCR RISK FOR T2D 1.8X (~5 to 10% per year) EVEN THOSE WITH GENETIC RISK, HELPED BY LIFESTYLE CHANGES/MEDS IF YOU DIDN’T HAVE GENETIC RISK, WOULD YOU WANT TO IGNORE BASELINE RISK? $300

9p21 SNP AND MI ABOUT 20-25% OF CAUCASIAN POPULATION HAVE 2 “G” SNPs RISK OF MI OVER 20 YEARS INCR FROM 13% TO 17% NOT RELATED TO CHOLESTEROL ETC

9p21 SNPs AND MI AND DIABETES!..? CLOSE BUT NO CIGAR!

PHARMACOGENETICS FARM...WHAT? STUDY OF HOW OUR GENES AFFECT THE WAY WE REACT TO DRUGS FIRST DOCUMENTED IN 1950s

PHARMACOGENETICS THERAPEUTIC “WINDOW” TOO LITTLE...NO HELP TOO MUCH...COMPLICA- TIONS DIFFERENT PEOPLE... DIFFERENT WINDOWS

PHARMACOGENETICS INH EXTREMELY IMPORTANT FOR CONTROL OF TUBERCULOSIS ABOUT 60% OF CAUCASIAN POPULATION “SLOW ACETYLATORS” REDUCED METABOLISM OF INH, SULFA DRUGS, THEOPHYLLIN, PROCAINAMIDE CAUSES TOXICITY DRUG INTERACTIONS

PHARMACOGENETICS CHEMOTHERAPY DRUGS SUCH AS AZATHIOPRINE AND MERCAPTOPURINE METABOLIZED BY TPMT GENE 2 NON-FUNCTIONING ALLELES ~ 100% RISK OF FREQUENTLY FATAL REACTION GENOTYPING NOW AVAILABLE

PHARMACOGENETICS CYP2D6 GENE STRONGLY AFFECTS METABOLISM OF OVER 30 DIFFERENT DRUGS ABOUT 10% WILL NOT DERIVE PAIN RELIEF FROM CODEINE SINCE IT MUST BE CONVERTED TO MORPHINE GENECHIP NOW AVAILABLE

PHARMACOGENETICS COUMADIN THERAPY VERY “NARROW WINDOW” 2 GENES (CYP2C9 AND VKORC1) SEEM TO CONTROL ABOUT 60% OF THE VARIATION IN RESPONSE TO COUMADIN TESTS UNDER WAY TO VERIFY THEY IMPROVE CARE

GENE…ENVIRONMENT rs SNP FTO gene Associated with type II DM DM not associated if adjusted for BMI Effect on BMI seen only in those with minimal physical activity P=0.007 NS

GENE…ENVIRONMENT APOA5 gene “T1131C” SNP Non-coding 7% C allele RR 2.5 for hyperlipidemia Highly predictive of FBS BUT….look at interaction with smoking! NS P=0.0003

WHAT ABOUT THE STRONG HEART STUDY GENETIC RESULTS?

THICK HEART WALL ON LEFT (LVH) CAUSES: –HYPERTENSION –VALVE PROBLEMS HARD FOR CORONARY ARTERIES TO PENETRATE NOT CAUSED BY EXERCISE LEFT VENTRICULAR HYPERTROPHY

Strong Heart Family Study: Prevalence of LVH by Age

SHS LINKAGE RESULTS LV Mass –Chromosome 12p –Arizona and Dakotas; but not Oklahoma –Goring HH et al, in press Obesity –Chromosome 4q35 –Goring HH et al, 2007 Components of metabolic syndrome –Hypertension: Chromosome 1 –Elevated lipids: Chromosome 12 –North KE et al, 2005

SHS LINKAGE RESULTS Systolic Blood Pressure –Chromosome 17q25 –In women but not men –8 SNPs tested in region –UTS2R gene SNP effects kidney function –Franceschini N et al, 2006 and in press ? Specific to Dakotas ? –LDL Cholesterol: Chromosome 19q13 –North KE et al, 2006 –Obesity: Chromosome 2p –Diego V et al, 2006

SHS LINKAGE RESULTS Kidney Function (Glomerular filtration rate) Chromosome 12 Mottl A, in press